Discussion on LYNPARZA

Written by patrippon on March 31, 2021.

When

03/31/21

6:00 pm - 7:00 pm

Virtual Expert Discussion on LYNPARZA® (olaparib)

Treatment of mCRPC with LYNPARZA:
An oral therapy for patients with HRR gene mutations following progression on enzalutamide or abiraterone

Presented by:

Kevin Lagman, MBA, MSN, APRN, FNP-C
Advanced Practice Provider, Department of Genitourinary
Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX

To register or for more information, contact
Lynn Harris at 626-622-2658 or lynn.harris@astrazeneca.com